Literature DB >> 11422003

Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis.

T N Johnson1, M S Tanner, C J Taylor, G T Tucker.   

Abstract

AIMS: To investigate the effects of age and disease states on the expression and activity of intestinal CYP3A4 in a paediatric population.
METHODS: Duodenal biopsies and surgical sections were collected from 104 paediatric patients (age range 2 weeks to 17 years) and from 11 foetuses. An S9 fraction was prepared in each case. CYP3A4 expression was assessed by Western blotting and by immunohistochemistry; activity was measured by the rate of formation of 6beta-hydroxytestosterone from testosterone. Villin expression was used as a marker of enterocyte harvest to normalize CYP3A4 expression and activity data.
RESULTS: In the 74 histologically normal paediatric biopsies there were statistically significant increases in CYP3A4 expression (r2 = 0.19, P = 0.001) and activity (r2 = 0.17, P = 0.02) with age. CYP3A4 was practically absent in fetal duodenum and was expressed at relatively low levels in neonates (P < 0.05 between neonates and children > 5 years). Active coeliac disease resulted in significant (P < 0.001) decreases in CYP3A4 expression and activity.
CONCLUSIONS: Duodenal CYP3A4 is present at significantly lower levels in neonates and in patients with active coeliac disease. This may have clinical significance with respect to the oral bioavailability of CYP3A4 substrates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422003      PMCID: PMC2014473          DOI: 10.1046/j.1365-2125.2001.01370.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  44 in total

Review 1.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

2.  Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease.

Authors:  R E Schneider; J Babb; H Bishop; M Mitchard; A M Hoare
Journal:  Br Med J       Date:  1976-10-02

Review 3.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.

Authors:  J B Houston; K E Kenworthy
Journal:  Drug Metab Dispos       Date:  2000-03       Impact factor: 3.922

4.  Characterization of human small intestinal cytochromes P-450.

Authors:  Q Y Zhang; D Dunbar; A Ostrowska; S Zeisloft; J Yang; L S Kaminsky
Journal:  Drug Metab Dispos       Date:  1999-07       Impact factor: 3.922

5.  Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.

Authors:  D Lacroix; M Sonnier; A Moncion; G Cheron; T Cresteil
Journal:  Eur J Biochem       Date:  1997-07-15

6.  Propranolol absorption in untreated coeliac disease.

Authors:  G I Sandle; A Ward; M D Rawlins; C O Record
Journal:  Clin Sci (Lond)       Date:  1982-07       Impact factor: 6.124

7.  CYP3A gene expression in human gut epithelium.

Authors:  J C Kolars; K S Lown; P Schmiedlin-Ren; M Ghosh; C Fang; S A Wrighton; R M Merion; P B Watkins
Journal:  Pharmacogenetics       Date:  1994-10

8.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.

Authors:  K S Lown; J C Kolars; K E Thummel; J L Barnett; K L Kunze; S A Wrighton; P B Watkins
Journal:  Drug Metab Dispos       Date:  1994 Nov-Dec       Impact factor: 3.922

9.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme.

Authors:  D J Waxman; C Attisano; F P Guengerich; D P Lapenson
Journal:  Arch Biochem Biophys       Date:  1988-06       Impact factor: 4.013

10.  Interaction between grapefruit juice and midazolam in humans.

Authors:  H H Kupferschmidt; H R Ha; W H Ziegler; P J Meier; S Krähenbühl
Journal:  Clin Pharmacol Ther       Date:  1995-07       Impact factor: 6.875

View more
  41 in total

1.  Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach.

Authors:  Trevor N Johnson; Farzaneh Salem; Masoud Jamei; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

2.  Response to: "Prediction of Voriconazole Non-Linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach".

Authors:  Nicole R Zane; Dhiren R Thakker
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

3.  Neonatal pharmacology: extensive interindividual variability despite limited size.

Authors:  Cuneyt Tayman; Maisa Rayyan; Karel Allegaert
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

Review 4.  Paediatric pharmacokinetics: key considerations.

Authors:  Hannah Katharine Batchelor; John Francis Marriott
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

5.  A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building.

Authors:  Khaled Abduljalil; Xian Pan; Amita Pansari; Masoud Jamei; Trevor N Johnson
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

6.  Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.

Authors:  Jean-Marie Nicolas; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

7.  Novel role of the serine protease inhibitor elafin in gluten-related disorders.

Authors:  Heather J Galipeau; Michelle Wiepjes; Jean-Paul Motta; Jessica D Schulz; Jennifer Jury; Jane M Natividad; Ines Pinto-Sanchez; Daniel Sinclair; Perrine Rousset; Rebeca Martin-Rosique; Luis Bermudez-Humaran; Jean Christophe Leroux; Joseph A Murray; Edgardo Smecuol; Julio C Bai; Nathalie Vergnolle; Philippe Langella; Elena F Verdu
Journal:  Am J Gastroenterol       Date:  2014-04-08       Impact factor: 10.864

Review 8.  Pediatric Dose Selection and Utility of PBPK in Determining Dose.

Authors:  Ian E Templeton; Nicholas S Jones; Luna Musib
Journal:  AAPS J       Date:  2018-02-13       Impact factor: 4.009

9.  Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.

Authors:  N C Sambol; L Yan; D J Creek; S A McCormack; E Arinaitwe; V Bigira; H Wanzira; A Kakuru; J W Tappero; N Lindegardh; J Tarning; F Nosten; F T Aweeka; S Parikh
Journal:  Clin Pharmacol Ther       Date:  2015-05-02       Impact factor: 6.875

10.  Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children.

Authors:  Tomoyuki Mizuno; Tsuyoshi Fukuda; Satohiro Masuda; Shinji Uemoto; Kazuo Matsubara; Ken-Ichi Inui; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.